Original Contributions |
From Humboldt University (Charité), Department of Physiology, Berlin (I.M.), and Max Delbrück Center for Molecular Medicine, Berlin-Buch (U.W., G.L., H.H., U.G., I.M.), Germany.
Correspondence to Prof Ingo Morano, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, 13122 Berlin-Buch, Germany. E-mail imorano{at}orion.rz.mdc-berlin.de
| Abstract |
|---|
|
|
|---|
-smooth muscle actin. Abundance of
the SM-MHC-B isoform in these cells was evaluated by using an antibody
raised against the sevenamino acid insert at the 25K/50K junction of
the myosin head (a25K/50K) that specifically recognized SM-MHC-B. In
the ventricle, a25K/50K immunoreactivity was observed in smooth muscle
cells of precapillary arterioles but not in larger vessels or aorta.
The a25K/50K immunoresponse of those vessels with the highest
expression level of SM-MHC-B closely resembled the signal observed in
the smooth muscle layer of urinary bladder known to preferentially
express SM-MHC-B. Interestingly, in left ventricles of stroke-prone
spontaneously hypertensive rats, there was a significantly reduced
fraction of a25K/50K-positive precapillary arterioles compared with
normotensive control rats.
Key Words: smooth muscle myosin heavy chain hypertrophy hypertension cardiac vessel
| Introduction |
|---|
|
|
|---|
Little is known about regulation of alternative splicing of MHC
and MLC isoforms in SMCs as well as functional consequences of
alternative splicing. During pregnancy, the B forms become
downregulated in the rat myometrium.11
Downregulation of the B forms could also be observed in the megacolon
in Hirschsprung's disease12 as well as in
hypertrophied urinary bladder.13 We recently
demonstrated that steroid hormones are involved in the regulation of
myosin subunit expression: testosterone but not estrogen favored the
expression of SM1 and 5'-inserted MHC, whereas estrogen reduced
it.14 MHCs containing the 25K/50K insert revealed
a higher ATPase activity and moved actin filaments faster in in vitro
motility assays than did MHCs without the 5'
insert.10 15 In physiological
experiments, however, downregulation of the SM-MHC-B isoforms in the
megacolon and pregnant myometrium is associated with an increased
shortening velocity.12 16 There is a
tissue-specific regulation of SM-MHC splicing. As demonstrated by mRNA
analysis,
85% of rat bladder MHCs contained the 25K/50K
insertion, whereas MHCs of rat aorta and myometrium contained very low
levels of SM-MHCs with 25K/50K insertion.8 The B
form has therefore been designated as the "intestinal" form, and
the A form has been designated as the "vascular" form.
In the present study, we investigated expression of the SM-MHC-B isoform in cardiac vessels of normotensive rats (WKY) and SHRSP using immunofluorescence microscopy. We found for the first time that SMCs of precapillary arterioles in the heart contain considerable amounts of the intestinal B form. In contrast, larger arteries contain predominantly the A form. Furthermore, SHRSP reveal a smaller fraction of precapillary arterioles in which detectable levels of the B form are found.
| Materials and Methods |
|---|
|
|
|---|
|
Antibody Preparation
A peptide antibody specific for the 25K/50K insertion
(a25K/50K) of rat SM-MHC (5' insert) was generated based on the
amino acid sequence QGPSFAY.8 At the amino
terminus of the peptide, N-chloroacetylglycine was added to
facilitate cross-linking to carriers. The peptide was synthesized by
the solid-phase method, purified, coupled to keyhole limpet
hemocyanine, and used for immunization of rabbits as described
previously.17 The resulting antibody fractions
were purified on a peptide-affinity column.14
Specificity of the antibody has been characterized
previously.11 14
Immunofluorescence Microscopy
Cryosections of 5-µm thickness were prepared with a Jung
Frigocut 2800N cryostat (Leica). Sections were fixed with 4%
formaldehyde in 0.1 mol/L phosphate buffer, pH 7.4, for 15 minutes at
room temperature. Immunolabeling was performed with a25K/50K (see
above) and aSM-actin antibodies (clone asm-1, Boehringer). In
double-labeling experiments, primary antibodies were visualized by
staining with DTAF- and Cy3-conjugated anti-rabbit and anti-mouse
secondary antibodies (Dianova). To suppress unspecific labeling,
cryosections were preincubated with a solution containing 20
mmol/L Tris-HCl, pH 8.4, 630 mmol/L NaCl, 0.05% Tween 20, 0.02%
NaN3, and 1% BSA (1% BSA-Tris) for 30 minutes
at room temperature. Primary and secondary antibodies were diluted with
the same solution to a protein concentration of 0.2 to 5 µg/mL and 5
to 20 µg/mL, respectively. Incubation with primary antibodies was
performed for 1 hour at 37°C, and incubation with secondary
antibodies was performed for 30 minutes at 37°C. During the
immunolabeling procedure, nuclei were stained
simultaneously by DAPI (Sigma). Washing steps were
performed with 1% BSA-Tris. To prove specificity of immunoreaction,
a25K/50K was preincubated with a 1600-fold molar excess of the peptide
corresponding to the 25K/50K-insert sequence at 4°C overnight. This
caused a complete suppression of the fluorescence signal (not
shown). Tissue sections were evaluated with an Axioplan
fluorescence microscope (Carl Zeiss) with appropriate filter
systems. Micrographs were taken with an MC100 automatic camera (Carl
Zeiss) with Kodak TMax 400 film.
To evaluate the fraction of cardiac vessels containing the SM-MHC-B isoform, all aSM-actinpositive and a25K/50K-positive vessels in a section were counted (two sections per ventricle, six animals per group). The fraction of a25K/50K-positive vessels was expressed in percentage of vessels detected by aSM-actin staining.
Statistical Evaluation
Results are expressed as mean±SD. Significance analysis
was performed with the Student's t test. In case of
significant differences between SDs, the nonparametric
Mann-Whitney test was used.
| Results |
|---|
|
|
|---|
10 µm and a lumen diameter
25 µm, with the
majority (
85%) in the range of
5 µm for wall thickness and
lumen diameter. From wall thickness and simultaneous
staining of nuclei with DAPI (Figure 2
|
|
The staining pattern of the a25K/50K antibody is virtually identical to
that of the aSM-actin antibody, as demonstrated at higher resolution in
Figure 2
. A cross-sectioned part (Figure 2A
through 2D
) and a
tangentially sectioned part (Figure 2E
through 2H
) of a small vessel
show unambiguously that SMCs stained specifically with the aSM-actin
antibody (Figure 2B
and 2F
) are also labeled with the a25K/50K antibody
(Figure 2A
and 2E
). Endothelial cells located in the
lumen of the vessel are not stained. The location of
endothelial cells is demonstrated by staining of their
nuclei with DAPI (Figure 2C
and 2G
) and by the structures visible in
the corresponding differential interference contrast images (Figure 2D
and 2H
). Thus, it can be concluded that SMCs of small
ventricular vessels express the B form of SM myosin.
To characterize the nature of vessels labeled with the a25K/50K
antibody in ventricular tissue, immunolabeling was
performed with cryostat sections of rat liver, where arterioles and
veins can be differentiated histologically according to
their specific location in liver lobules. As can be seen in Figure 3
, small vessels were intensively stained
by the a25K/50K antibody, whereas the larger vein of the portal
triangle did not show any immunoreaction. We therefore suppose that
a25K/50K-positive vessels in liver and heart tissue are arterioles,
whereas a25K/50K-negative vessels are venules. In summary, the
immunofluorescence data characterize precapillary
arterioles of rat ventricular tissue as sites of SM-MHC-B
expression.
|
In another set of experiments we compared the proportion of
a25K/50K-labeled vessels in left ventricles of WKY and SHRSP. As shown
in Table 2
, the proportion of
a25K/50K-positive vessels was significantly higher in WKY than in
SHRSP, the difference amounting to
17% related to the total number
of counted vessels. In both rat strains the percentage of vessels with
a wall thickness >10 µm was
5%, and no a25K/50K-positive
vessels were found in this size range. Therefore, we conclude that the
difference in the percentage of a25K/50K-positive vessels resulted from
differences in SM-MHC-B abundance in ventricular vessels of
WKY and SHRSP.
|
Semiquantitative Evaluation of SM-MHC-B Level by
Immunoblotting and Immunofluorescence
Microscopy
To compare the level of SM-MHC-B in cardiac vessels with that of
other tissues with known expression level of SM-MHC-B, Western blot
analyses were performed with the a25K/50K antibody and
SDS-extracted proteins from the aorta, bladder, and left ventricle of
WKY. The antibody reacted strongly and specifically with the 200-kDa
MHC band in bladder (Figure 4
, lanes 4 to
6), whereas no immunoreaction was obtained with SM-MHC of aorta (Figure 4
, lanes 1 to 3) and left ventricle (not shown). No cross-reactivity
with other proteins was observed. These results confirm previous data
demonstrating predominant expression of SM-MHC-B in urinary
bladder8 and are in accordance with the
immunofluorescence studies described above with
respect to a very low level of SM-MHC-B in ventricular
tissue. Obviously, in protein extracts of the ventricle, the
concentration of SM-MHC originating from cardiac vessels did not reach
the detection limit in the Western blot analysis.
|
Additional immunofluorescence studies were
performed with cryostat sections of urinary bladder and aorta to
compare the immunoreaction of the a25K/50K antibody in two tissues with
very different expression levels of SM-MHC-B. In accordance with the
results of immunoblotting, no a25K/50K staining was
seen in aorta (not shown), whereas double-labeling experiments with
aSM-actin and a25K/50K antibodies performed on cryostat sections of
urinary bladder revealed that the SM layer of bladder wall as well as
SMCs of small vessels were strongly labeled by both antibodies (Figure 5
). Similar to cardiac tissue, we
observed vessels that were labeled solely with the aSM-actin antibody
but not with the a25K/50K antibody (large arrows in Figure 5
). To
evaluate the SM-MHC-B level, double-labeling experiments were performed
with decreasing concentrations of the a25K/50K antibody (4 to 0.2
µg/mL) and constant concentrations of the aSM-actin antibody on
cryostat sections of left ventricles and urinary bladder of WKY. As
expected, staining intensity in urinary bladder gradually decreased
with antibody dilution, suggesting very similar levels of SM-MHC-B
throughout the SMC layer of urinary bladder wall. In
ventricular tissue, however, the number of positively
reacting precapillary arterioles declined from
75% at an antibody
concentration of 4 µg/mL to
5% at an antibody concentration of
0.2 µg/mL (related to aSM-actinpositive vessels). Below an a25K/50K
antibody concentration of 0.2 µg/mL, no fluorescence signal
was observed in either bladder or ventricular tissue. This
finding indicates the existence of different levels of SM-MHC-B in
ventricular precapillary arterioles. Furthermore, the data
show that the highest level of SM-MHC-B in SMCs of
ventricular precapillary arterioles, ie, in positively
reacting vessels at an antibody concentration of 0.2 µg/mL, closely
resembles that of SMCs of urinary bladder.
|
| Discussion |
|---|
|
|
|---|
The physiological importance of the observation of
considerable amounts of SM-MHC-B in cardiac blood vessels is still not
clear because of the conflicting results of experiments performed in
vitro and in physiological models. In vitro,
SM-MHCs with the 25K/50K insertion revealed a higher
actin-activated ATPase activity as well as a higher velocity of
actin filament sliding in the in vitro motility
assay.10 15 Results obtained by in vitro motility
assays predict an increased shortening velocity. However, this could
not be verified in physiological experiments.
Although
85% of SM-MHC mRNA of the rat bladder contained the
5'-insertion,8 it has a maximal shortening
velocity that is very similar to that of the
myometrium,11 where only minor amounts of
5'-inserted SM-MHCs are found.8 Furthermore,
although rat myometrium and aorta contain comparable low levels of the
5' insertion,8 they revealed very different
shortening velocities (compare Reference 1616 with Reference 1919 ). In the
hypertrophied myometrium during pregnancy11 16
and in the megacolon in Hirschsprung's
disease,12 decreased expression of the SM-MHC-B
form was observed, while maximal shortening velocity increased. At
least in the megacolon, this increased shortening velocity was
independent of changes of 17-kDa MLC
isoforms.12
Another important finding of the present study is that the amount of the relevant cardiac vessels that contained the 5'-inserted MHCs was significantly lower in SHRSP than in normotensive age-matched controls (WKY). This difference is most likely due to a decreased level of SM-MHC-B in SHRSP, which may result from elevated splicing activity in this hypertensive rat strain. On the other hand, it cannot be excluded that in SHRSP a reduction in SM-MHC transcription occurs, resulting in less of each isoform. However, this seems unlikely because, for example, pressure-induced hypertrophied SMCs revealed no reduction in force generation20 or myosin content.21 Although the physiological role of 5'-inserted MHC is not completely clear, some speculations may be allowed because of the finding that in the hypertrophied myometrium10 16 and colon12 the SM-MHC-B form expression decreased, while maximal shortening velocity increased. Since maximal shortening velocity reflects the detachment rate constant of myosin cross-bridges (gapp22 ), we suggest that the SM-MHC-B isoform remains for a longer time in the force-generating state than the alternatively spliced A form. Any shift of the ratio between the attachment rate (fapp) and the detachment rate (gapp) (fapp/gapp) changes the force-calcium relationship.23 Our prediction, therefore, is a leftward shift of the force-calcium relationship (increased Ca2+ sensitivity) of cardiac vessels expressing the B form compared with those with the A form. Furthermore, since both ATP consumption (which equals fappgapp/[fapp+gapp]) and force (which equals fapp/[fapp+gapp]) (Reference 2222 ) depend on gapp, a more economical force production in the presence of the B form would be allowed. In essential hypertension, this economizing capacity would be reduced as a result of decreased abundance of the SM-MHC-B forms.
In summary, we observed expression of the intestinal SM-MHC isoform in the cardiac arteries located farthest downstream, namely, the precapillary arterioles. The level of the isoform is reduced in the hypertrophied heart of hypertensive animals.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received September 24, 1997; accepted May 14, 1998.
| References |
|---|
|
|
|---|
2.
Leinwand LA, Fournier REK, Nadal-Ginard B, Shows TB.
Isolation and characterization of human myosin heavy chain genes.
Proc Natl Acad Sci U S A. 1983;80:37163720.
3.
Swynghedauw B. Developmental and functional adaptation
of contractile proteins in cardiac and skeletal muscles. Physiol
Rev. 1986;66:710771.
4. Somlyo AP. Myosin isoforms in smooth muscle: how may they affect function and structure? J Muscle Res Cell Motil. 1993;14:557563.[Medline] [Order article via Infotrieve]
5.
Rovner AS, Thompson MM, Murphy RA. Two different
myosin heavy chains are found in smooth muscle. Am J
Physiol. 1986;250:C861C870.
6.
Nagai R, Kuro-o M, Babij P, Periasamy M.
Identification of two types of smooth muscle myosin heavy chain
isoforms by cDNA cloning and immunoblot analysis.
J Biol Chem. 1989;264:97349737.
7. Hamada Y, Yanagisawa M, Katsugarawa Y, Coleman JR, Nagata S, Matsuda G, Masaki T. Distinct vascular and intestinal smooth muscle myosin heavy chain mRNAs are encoded by a single-copy gene in the chicken. Biochem Biophys Res Commun. 1990;170:5358.[Medline] [Order article via Infotrieve]
8.
White S, Martin A, Periasamy M. Identification of a
novel smooth muscle myosin heavy chain cDNA: isoform diversity in the
S1 head region. Am J Physiol. 1993;264:C1252C1258.
9.
Babij P. Tissue-specific and developmentally regulated
alternative splicing of a visceral isoform of smooth muscle myosin
heavy chain. Nucl Acids Res. 1993;21:14671471.
10.
Kelley CA, Takahashi M, Yu JH, Adelstein RS. An
insert of seven amino acids confers enzymatic differences between
smooth muscle myosins from the intestines and vasculature. J
Biol Chem. 1993;268:1284812854.
11. Haase H, Morano I. Alternative splicing of smooth muscle myosin heavy chains and its functional consequences. J Cell Biochem. 1996;60:521520.[Medline] [Order article via Infotrieve]
12.
Siegman M, Butler TM, Mooers SU, Trinkle-Mulcahy L,
Narayan S, Chacko AL, Haase H, Morano I. Hypertrophy of
colonic smooth muscle: contractile proteins, shortening velocity, and
regulation. Am J Physiol. 1997;272:G1571G1580.
13. Sjuve R, Haase H, Morano I, Uvelius, Arner A. Contraction kinetics and myosin isoform composition in smooth muscle from hypertrophied rat urinary bladder. J Cell Biochem. 1996;63:8693.[Medline] [Order article via Infotrieve]
14. Calovini T, Haase H, Morano I. Steroid hormone regulation of myosin subunit expression in smooth and cardiac muscle. J Cell Biochem. 1995;59:6978.[Medline] [Order article via Infotrieve]
15. Rovner A, Freyzon Y, Trybus KM. An insert in the motor domain determines the functional properties of expressed smooth muscle myosin isoforms. J Muscle Res Cell Motil. 1997;18:103110.[Medline] [Order article via Infotrieve]
16. Morano I, Erb, G, Sogl B. Expression of myosin heavy and light chains changes during pregnancy in the rat uterus. Pflugers Arch. 1993;423:434441.[Medline] [Order article via Infotrieve]
17. Haase H, Karczewski P, Beckert R, Krause EG. Phosphorylation of the L-type Ca channel ß subunit is involved in ß adrenergic signal transduction. FEBS Lett. 1993;335:217222.[Medline] [Order article via Infotrieve]
18.
DiSanto ME, Cox RH, Wang Z, Chacko S.
NH2-terminal-inserted myosin II heavy chain is expressed in smooth
muscle of small muscular arteries. Am J Physiol. 1997;272:C1532C1542.
19. Malmqvist U, Arner A. Correlation between isoform composition of the 17 kDa myosin light chain and maximal shortening velocity in smooth muscle. Pflugers Arch. 1991;418:423530.[Medline] [Order article via Infotrieve]
20.
Arner A, Uvelius B. Force-velocity characteristics and
active tension in relation to content and orientation of smooth muscle
cells in aortas from normotensive and spontaneously hypertensive rats.
Circ Res. 1982;50:812821.
21.
Malmqvist U, Arner A. Isoform distribution and tissue
contents of contractile and cytoskeletal proteins in hypertrophied
smooth muscle from rat portal vein. Circ Res. 1990;66:832845.
22. Huxley AF. Muscle structure and theories of contraction. Prog Biophys Chem. 1957;7:255318.
23. Brenner B. The cross-bridge cycle in muscle: mechanical, biochemical, and structural studies in single skinned rabbit psoas fibers to characterize cross-bridge kinetics in muscle for correlation with the actomyosin-ATPase in solution. Basic Res Cardiol. 1986;81(suppl 1):115.
This article has been cited by other articles:
![]() |
F. R. Gil, N. B. Zitouni, E. Azoulay, K. Maghni, and A.-M. Lauzon Smooth muscle myosin isoform expression and LC20 phosphorylation in innate rat airway hyperresponsiveness Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L932 - L940. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Leguillette, F. R. Gil, N. Zitouni, S. Lajoie-Kadoch, A. Sobieszek, and A.-M. Lauzon (+)Insert smooth muscle myosin heavy chain (SM-B) isoform expression in human tissues Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1277 - C1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Babu, G. J. Pyne, Y. Zhou, C. Okwuchukuasanya, J. E. Brayden, G. Osol, R. J. Paul, R. B. Low, and M. Periasamy Isoform switching from SM-B to SM-A myosin results in decreased contractility and altered expression of thin filament regulatory proteins Am J Physiol Cell Physiol, September 1, 2004; 287(3): C723 - C729. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Payne, H.-Y. Zhang, Y. Shirasawa, Y. Koga, M. Ikebe, J. N. Benoit, and S. A. Fisher Dynamic changes in expression of myosin phosphatase in a model of portal hypertension Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1801 - H1810. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Tuck, K. Maghni, A. Poirier, G. J. Babu, M. Periasamy, J. H. T. Bates, R. Leguillette, and A.-M. Lauzon Time Course of Airway Mechanics of the (+)Insert Myosin Isoform Knockout Mouse Am. J. Respir. Cell Mol. Biol., March 1, 2004; 30(3): 326 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Stiebellehner, M. G. Frid, J. T. Reeves, R. B. Low, M. Gnanasekharan, and K. R. Stenmark Bovine distal pulmonary arterial media is composed of a uniform population of well-differentiated smooth muscle cells with low proliferative capabilities Am J Physiol Lung Cell Mol Physiol, October 1, 2003; 285(4): L819 - L828. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Van Gieson, W. L. Murfee, T. C. Skalak, and R. J. Price Enhanced Smooth Muscle Cell Coverage of Microvessels Exposed to Increased Hemodynamic Stresses In Vivo Circ. Res., May 2, 2003; 92(8): 929 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wetzel, O. Baltatu, B. Nafz, P. B. Persson, H. Haase, and I. Morano Expression of smooth muscle MyHC B in blood vessels of hypertrophied heart in experimentally hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R607 - R610. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |